The global biosimilars market size was valued at USD 37.73 billion in 2025 and is projected to grow from USD 42.80 billion in 2026 to USD 117.28 billion by 2034, registering a CAGR of 13.43% during the forecast period from 2026 to 2034. Europe dominated the biosimilars market with a market share of 38.5% in 2025.
Biosimilars are biological medicines developed to be highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, efficacy, or quality. Manufactured using living cells, they undergo rigorous analytical, preclinical, and clinical evaluations to ensure comparable therapeutic performance. Biosimilars are widely used across various therapeutic areas to expand patient access to biologic treatments while supporting cost-effective healthcare.
Download a Free Sample To learn more about this report,
Adoption of Advanced Analytical Characterization Technologies
The need for precise comparison between biosimilars and reference biologics is increasing the use of advanced analytical methods that assess structural, physicochemical, and functional characteristics. FDA guidance identifies comparative analytical studies as the foundation of biosimilar development, while newer approaches are designed to detect relevant product differences with greater sensitivity. This shift can strengthen evidence of biosimilarity and may reduce the need for some additional clinical testing when scientifically justified.
Development of Biosimilars for High-Cost Biologic Therapies
The high cost of many biologic medicines is encouraging developers to pursue biosimilar versions of established therapies with significant treatment costs. FDA reported that biosimilars generated $20 billion in U.S. healthcare savings during 2024, highlighting the economic impact of competition from these products. This development can expand access to biologic treatments while creating lower-cost alternatives for therapies used in areas such as cancer and autoimmune diseases.
Biologic Cost Reduction and Patent Expiry Drive Market
The high cost of biologic therapies creates demand for lower-cost treatment alternatives that can improve affordability for patients and healthcare systems. FDA reports that biosimilars generated about $56.2 billion in U.S. healthcare savings from 2015 through 2024, including $20.2 billion in savings during 2024 alone. For example, biosimilars used in oncology, autoimmune diseases, and diabetes can provide additional treatment options when biologic costs create access challenges. This cost-management need supports biosimilar adoption and encourages manufacturers to supply competitively priced biologic alternatives.
The expiry of reference-product exclusivity creates opportunities for manufacturers to enter biologic markets with biosimilar alternatives. FDA states that a biosimilar application generally cannot be approved until 12 years after the reference product was first licensed in the U.S., subject to applicable exclusivities and other requirements. For example, FDA approved 18 biosimilars for 10 reference products during 2025, including biosimilars referencing Novolog, Xolair, and Perjeta. This market-entry opportunity supports biosimilar development and broadens the supply of biologic treatment alternatives.
Pricing Pressure and Limited Awareness Restrain Market Expansion
Pricing pressure and low profit margins can arise as biosimilar manufacturers compete by offering lower prices than reference biologics. FDA reports that biosimilars in the U.S. typically launched with initial list prices 15% to 35% below reference products, creating strong price competition. Lower prices can reduce potential returns and make investment in additional biosimilar products less attractive, limiting manufacturer participation and slowing market expansion.
Limited awareness of biosimilar equivalence can create uncertainty among physicians and patients about the safety, effectiveness, and quality of biosimilars. FDA has identified improving communication and understanding among clinicians, payers, and patients as an important part of increasing biosimilar adoption, while its 2025 fact sheet notes that provider hesitancy and patient concerns about switching persist. This uncertainty can reduce prescribing and switching decisions, slowing biosimilar adoption and market growth.
Biosimilar CDMO Services and Patient Support Programs Offers Growth Opportunities
Biosimilar developers and pharmaceutical companies can use CDMO partners for cell-line development, process development, analytical development, and commercial manufacturing. Samsung Biologics reports 845 kL of total biomanufacturing capacity and 145+ global clients, creating revenue through development contracts, manufacturing agreements, and long-term production partnerships.
Biosimilar manufacturers, specialty pharmacies, and healthcare providers can provide treatment education, reimbursement assistance, and patient support services to improve treatment continuity. Sandoz reported 1.915 million patient treatments with its biosimilars in 2025 and provides patient and provider support for products such as Tyruko, creating additional value through support programs and stronger product adoption.
Biological Input Supply and Market Access Complexity Hinders Growth
Biosimilar manufacturers depend on specialized cell lines, culture media, filtration materials, chromatography resins, and other inputs that must meet stringent quality specifications. Unavailability of component materials and manufacturing supplies can affect the production of biological products and disrupt manufacturing continuity. Such interruptions can increase procurement costs, delay manufacturing, and make it harder for companies to maintain consistent product availability.
Biosimilar developers may face additional requirements when seeking interchangeability, which can affect pharmacy-level substitution depending on state laws. Evolving requirements can complicate commercialization strategies and create additional planning and evidence-generation needs for manufacturers seeking broader market access. These complexities can delay product uptake and make market expansion more difficult.
The monoclonal antibodies segment accounted for a 42.8% share in 2025 and is expected to grow at a CAGR of 19.6% during the forecast period 2026-2034, driven by the increasing adoption of biosimilar monoclonal antibodies, growing demand for cost-effective biologic therapies, and expanding use across oncology, autoimmune diseases, and other therapeutic areas. the growing number of regulatory approvals, increasing competition among biologic manufacturers, and rising healthcare expenditure further strengthen the segment’s dominant position in the biosimilars market.
The insulin analogs segment supports biosimilar adoption through diabetes treatment and increasing demand for affordable insulin therapies, while granulocyte colony-stimulating factors contribute through supportive care in oncology and other clinical applications. the erythropoiesis-stimulating agents segment supports treatment of anemia associated with chronic diseases and cancer, while the others segment includes additional biosimilar drug classes used across various therapeutic applications.
Request Customizationto receive a tailored report.
The oncology segment accounted for a share of 37.4% in 2025, owing to the high prevalence of cancer, increasing adoption of biologic therapies, and growing demand for cost-effective oncology treatments. the increasing availability of biosimilar oncology medicines, rising healthcare expenditure, and expanding access to affordable cancer therapies further strengthen the segment’s dominant position in the biosimilars market.
The ophthalmology segment is expected to grow at a CAGR of 20.2% during the forecast period, driven by increasing prevalence of ophthalmic disorders, growing adoption of biologic treatments for eye diseases, and rising demand for cost-effective therapeutic alternatives. the expansion of biosimilar availability in ophthalmology, increasing regulatory approvals, and growing access to affordable biologic therapies further support growth of the segment. the autoimmune & inflammatory diseases segment contributes through treatments for conditions such as rheumatoid arthritis and inflammatory disorders, while diabetes supports demand for biosimilar insulin therapies. the blood disorders segment includes applications in anemia and other hematological conditions, while others covers additional therapeutic indications.
The hospital pharmacies segment accounted for a share of 58.6% in 2025 due to their established role in dispensing specialized biologic medicines, direct integration with healthcare providers, and high demand for biosimilars in hospital-based treatments. the growing number of patients receiving biologic therapies, increasing adoption of biosimilars in hospitals, and established procurement and distribution systems further strengthen the segment’s dominant position in the biosimilars market.
The online pharmacies segment is expected to grow at a CAGR of 21.4% during the forecast period, fueled by increasing adoption of digital healthcare services, growing consumer preference for convenient medicine delivery, and expanding availability of biosimilar products through online platforms. the increasing penetration of e-pharmacy services, improved digital access to medicines, and growing acceptance of online prescription fulfillment further support growth of the segment. the drug stores and retail pharmacies segment continues to support biosimilar distribution through broad geographic accessibility and established retail networks.
Speak to an Analystto discuss market opportunities.
The Europe biosimilars market accounted for the largest regional share of 38.5% in 2025, supported by established biosimilar adoption, supportive regulatory frameworks, and growing demand for cost-effective biologic therapies. In the U.K. biosimilars market, the medicines and healthcare products regulatory agency updated its guidance in July 2026 on the biosimilar Work Sharing Initiative, which coordinates regulatory assessments with international partners to increase review capacity and support timely access to high-quality biosimilar medicines. The U.K. also maintains dedicated licensing guidance for biosimilar products.
In the Germany biosimilars market, the federal institute for drugs and medical devices continues to participate in european regulatory procedures for human medicines, including biosimilar products, through the EU medicines regulatory framework. In 2026, Germany remained involved in coordinated european assessments and pharmacovigilance activities for biological medicines, supporting the regulatory infrastructure for biosimilar adoption. Meanwhile, the France biosimilars market is supported by expanded pharmacist substitution, with france extending substitution to 11 biological molecules in 2026, including adalimumab, aflibercept, etanercept, filgrastim, ranibizumab, and ustekinumab. From september 1, 2026, the third-party payment system was also extended to substitutable biosimilars, while France's health insurance system provides financial incentives for physicians prescribing biosimilars, supporting wider adoption of these medicines.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific biosimilars market is expected to grow at a CAGR of 20.8%, showcasing the fastest-growing regional market, driven by expanding healthcare access, increasing biosimilar development and manufacturing, and rising demand for affordable biologic treatments. In Japan, the Japan biosimilars market is supported by measures from the ministry of health, labour and welfare to promote biosimilar uptake, including an updated reimbursement-related list in march 2026 and a target for biosimilars to account for at least 60% of eligible active ingredients by fiscal 2029.
In China, the China biosimilars market is supported by strengthened pharmaceutical manufacturing oversight, with the national medical products administration reinforcing contract manufacturing requirements in april 2026, including effective quality-management systems and compliance with drug GMP, supporting reliable biologics and biosimilars production. In South Korea, the South Korea biosimilars market is supported by revised biosimilar approval procedures announced in may 2026, introducing pre-submission meetings and rolling review for applications from october 1, 2026, which is expected to streamline the regulatory process. In India, the India biosimilars market is supported by continued development of the regulatory framework for similar biologics, with the central drugs standard control organisation inviting comments on revised guidelines in may 2025 covering requirements for biosimilar marketing authorization and development.
The North America biosimilars market accounted for a regional share of 28.7% in 2025, supported by increasing biosimilar adoption, expanding availability of lower-cost biologic alternatives, and growing healthcare expenditure. The U.S. biosimilars market is supported by continued expansion of the biosimilar approval pathway and increasing availability of lower-cost biologic alternatives. The FDA reported that 18 biosimilars for 10 reference products were approved in 2025, including several interchangeable biosimilars, bringing the total number of FDA-approved biosimilars to 81 for 20 different reference products since 2015.
The Canada biosimilars market is supported by health Canada’s established regulatory framework and increasing adoption of biosimilar biologic drugs. Health Canada states that biosimilars are authorized using the same rigorous standards for quality, safety, and efficacy as other biologic drugs, while provincial and territorial switching policies have contributed to increased biosimilar use in medical practice.
The Middle East and Africa biosimilars market is expected to grow at a CAGR of 15.7%, driven by improving access to biologic therapies, increasing healthcare investments, and growing adoption of cost-effective treatment options. The UAE biosimilars market is expected to benefit from increasing localization of pharmaceutical manufacturing and development of biologic medicines. In 2025, the department of health – abu dhabi and abbott announced a collaboration to localize pharmaceutical products and explore the development of biosimilars, supported by regulatory alignment and local capability-building initiatives. In 2026, abu dhabi also continued expanding its life sciences ecosystem and pharmaceutical supply-chain infrastructure, supporting future development and access to biosimilar medicines.
The Africa biosimilars market is expected to benefit from stronger regulatory harmonization, local pharmaceutical manufacturing, and efforts to improve access to quality-assured medicines. In may 2026, WHO and the african medicines agency signed a framework agreement to advance regulatory harmonization and convergence and improve access to safe, effective, and quality-assured health products across Africa. In august 2026, african health ministers also endorsed the regional strategy on regulation of medical products in the african region 2026–2035, supporting stronger regulatory systems and expanded local manufacturing of medicines.
The biosimilars market is moderately fragmented, with pharmaceutical companies, biotechnology companies, generic drug manufacturers, specialty biopharmaceutical firms, contract development and manufacturing organizations, and biosimilar developers competing across oncology, immunology, diabetes, hematology, and other therapeutic areas. Established players compete primarily on product quality, clinical evidence, regulatory compliance, manufacturing capabilities, biosimilar development expertise, pricing, portfolio breadth, supply reliability, strategic partnerships, and global commercialization networks, with leading players such as celltrion inc., sandoz group ag, biocon, samsung bioepis, and amgen inc. estimated to account for approximately 45% of the global market based on their biosimilar portfolios, manufacturing capabilities, regulatory approvals, geographic presence, and commercialization networks.
Emerging and regional players within the biosimilars market ecosystem compete through cost-effective manufacturing, streamlined development processes, specialized biosimilar portfolios, competitive pricing, localized regulatory expertise, flexible production capabilities, strategic collaborations, and expanded access to address diverse healthcare requirements and strengthen their market presence. these players also focus on developing targeted biosimilar portfolios, optimizing manufacturing processes, and expanding regional market access to differentiate their offerings and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
Autoimmune Disease Diagnostics Market Size, Share, Growth, 2034
Cannabis Testing Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com